Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while ...
By Michael Erman and Mrinalika Roy Jan 21 (Reuters) - Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of ...
The healthcare company’s forecast for 2026 tops Wall Street’s expectations.
Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood ...
Zacks Investment Research on MSN
J&J stock down despite Q4 earnings beat, oncology drugs drive sales
Johnson & Johnson’s JNJ fourth-quarter 2025 earnings came in at $2.46 per share, which beat the Zacks Consensus Estimate of ...
As we have previously reported, a group of health insurers and health insurance administrators (collectively, “CareFirst”) filed a class action complaint in 2023 against Johnson & Johnson and Janssen ...
In an extension of a phase 2 clinical drug trial, the treatment Stelara showed long-term favorable results for people with active lupus after taking the medication for two years. Both overall disease ...
Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback